Expression of sPD-L1 levels in an ex vivo liver perfusion model
Clinical and Experimental Immunology · 2025
DOI: 10.1093/cei/uxae094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Christian Irsara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: B7-H1 Antigen, Liver, Liver Transplantation, Reperfusion Injury. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The programmed cell death protein 1 (PD-1) acts as a central inhibitory immune checkpoint receptor. The soluble form of its primary ligand, sPD-L1, was found to be elevated in the serum of patients with cancer, infectious diseases, and chronic inflammation. So far, the hepatic origin of sPD-L1 has received relatively little attention and is therefore the subject of this study in the context of normothermic machine perfusion (NMP) of liver grafts. sPD-L1 concentrations as well as several well-established clinically relevant laboratory parameters were determined in the perfusate of 16 donor liver grafts undergoing NMP up to 30 hours. sPD-L1 levels continuously increased during NMP and significantly correlated with markers of hepatic synthesis (cholinesterase), acute-phase proteins (von Willebrand factor, procalcitonin, antithrombin, interleukin-6, fibrinogen), and liver decay markers (gamma-glutamyltransferase, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase). Perfusate leukocytes were in the lower reference range and decreased after 12 hours. Mean sPD-L1 levels in the perfusate correlated with donor levels of gamma-glutamyltransferase, alanine aminotransferase, creatinine, and blood urea nitrogen. Our study reveals a significant increase in the concentration of sPD-L1 following ischemia-reperfusion injury in a hepatic ex vivo model. sPD-L1 concentrations during NMP correlate with established acute-phase proteins and liver cell decay markers, suggesting that hepatic sPD-L1 synthesis or shedding increases during the acute phase and cell decay. Furthermore, sPD-L1 correlates with established liver function and synthesis parameters as well as with donor laboratory values and might therefore be a potential biomarker for the hepatic function of liver grafts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria.
- Department of Visceral, Transplant and Thoracic Surgery, and organLifeTM Laboratory, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.
ORCID-Profile: Lorin Loacker
Zitieren
APA
Irsara, C., Weissenbacher, A., Krendl, F. J., Anliker, M., Hofmann, J., Hautz, T., Schneeberger, S., Griesmacher, A., & Loacker, L. (2025). Expression of sPD-L1 levels in an ex vivo liver perfusion model. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae094
Vancouver
Irsara C, Weissenbacher A, Krendl FJ, Anliker M, Hofmann J, Hautz T, et al. Expression of sPD-L1 levels in an ex vivo liver perfusion model. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae094
BibTeX
@article{Irsara2025,
author = {Irsara, Christian and Weissenbacher, Annemarie and Krendl, Felix Julius and Anliker, Markus and Hofmann, Julia and Hautz, Theresa and Schneeberger, Stefan and Griesmacher, Andrea and Loacker, Lorin},
title = {Expression of sPD-L1 levels in an ex vivo liver perfusion model},
journal = {Clinical and Experimental Immunology},
year = {2025},
doi = {10.1093/cei/uxae094}
}
EUVIMED